Summary. The effect of glucagon infusion on hepatic glucose production during euglycaemia was evaluated in seven Type i (insulin-dependent) diabetic patients and in ten control subjects. In the diabetic subjects normoglycaemia was maintained during the night preceding the study by a variable intravenous insulin and glucose infusion. During the study endogenous insulin secretion was suppressed by somatostatin (450gg/h) and replaced by insulin infusion (0.15 mU. kg -1. min-9. 3H-glucose was infused for isotopic determination of glucose turnover. Plasma glucose was damped at 5 mmol/1 for 2 h 30 min and glucagon (1.5 ng. kg -1. min-0 was then infused for the following 3 h. Hepatic glucose production and glucose utilisation were measured during the first, second and third hour of the glucagon infusion. Basal hepatic glucose production (just prior to glucagon infusion) was similar in diabetic (1.2 +0.3 rag. kg -1. min -1) and control (1.6 _+ 0.1 mg-kg -1. min-0 subjects. In diabetic patients hepatic glucose production rose slowly to 2.1 _+ 0.5 mg. kg -1-min -1 during the first hours of glucagon infusion and stabilized at this level (2.4 + 0.5 mg. kg -1. min 1) in the third hour. In control subjects hepatic glucose production increased sharply to higher levels than in the diabetic subjects (3.4 + 0.3 mg. kg -~. min -1) during the first and second hour of glucagon infusion (p < 0.05) and then gradually fell (2.9 + 0.4 mg. kg-1. min-1) during the third horn, In conclusion, when stimulated with glucagon at a physiologic plasma concentration diabetic patients had 1) an overall reduced hepatic glucose production response and 2)an abnormal sluggish response pattern. These abnormalities mayimply inappropriate counter-regulation following a hypoglycaemic episode.
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Hypoglycaemia is a frequent complication of Type i (insulin-dependent) diabetes mellitus, and 10% of patients on conventional insulin therapy suffer at least one severe episode per year [1] . The incidence of hypoglycaemia is reported to be increased approximately three-fold during intensive insulin therapy (multiple injection regimens) [1, 2] .
Early studies of counter-regulation in short-term hypoglycaemia [3, 4] and more prolonged hyperinsulinaemia [5] as well as studies using the pituitary-adrenal-pancreatic clamp technique [6, 7] in more prolonged hypoglycaemia have shown that counter-regulation initially mainly involves changes in hepatic glucose production (HGP). These changes are due predominantly to glucagon and epinephrine. With more prolonged hypoglycaemia, suppression of glucose utilisation becomes manifest due to the increasing roles of growth hormone (GH) and cortisol [8, 9] . A glucose autoregulatory effect on the liver as well as in the periphery has also been implicated [10, 11] . In the diabetic patient, in whom counter-regulatory responses are of particular importance, various defects have been reported to enhance the tendency to hypoglycaemia [1, 12, 13] . These abnormalities include the presence of insulin antibodies [14] and selective impaired glucagon response to hypoglycaemia after about 5 years of diabetes [14] , in Type 2 (non-insulin-dependent) [15] as well as Type 1 diabetes mellitus [14] . Furthermore, after 5 to 10 years of disease a diminished epinephrine response has also been reported in some patients [16, 17] .
With a defective hormonal response to hypoglycaemia the sensitivity to physiological levels of glucagon (and epinephrine) becomes particularly important. However, this issue has not previously been investigated in detail.
Apart from an important function in the acute prevention/recovery from hypoglycaemia, glucagon is a primary determinant of HGP in the post-absorptive state and is responsible for the majority of glucose output [18] . It also plays a significant role in other situations where the need for glucose production is increased. During extended exercise increments in glucagon concentrations have been shown to increase HGP significantly in humans [19, 20] . In the initial stages of starvation and after a protein rich meal glucagon has an essential function in securing glucose supply to the brain [21, 22] . Also, it has been shown to be one of the factors responsible for stress-induced hyperglycaemia [23] . Basal plasma glucagon levels increase HGP mainly by stimulating glycogenolysis, whereas with higher plasma glucagon levels, a stimulatory effect on gluconeogenesis is also evident [24] . Small experimental increments in plasma gulcagon concentrations have been shown to have marked stimulatory effects on HGP [18] .
The purpose of this study was to evaluate hepatic sensitivity to modest increments of glucagon in Type 1 diabetes. (Table 1) Seven C-peptide negative diabetic (six male, one female) and ten healthy subjects (nine male, one female) were studied. At that time the age of the diabetic subjects was 31 +_ 7 years and the control subjects 27 +_ 1 years. Height and weight were similar in the two groups. The control subjects were healthy volunteers, none had a family history of diabetes or were taking any drugs. The diabetic subjects were volunteers from the out-patient clinic of the participating hospitals. Apart from diabetes they had no other diseases and kidney function was normal.
Subjects and methods

Subjects
Mean HbAlc value of the diabetic subjects prior to the experiment described was 7.7 + 0.9% (range: 5.6-12%). Mean duration of disease was 12 +_ 4 years (range:l-30 years). Informed consent was obtained from all participants and the protocol of study was approved by the regional ethical committee.
Experimental design (Fig. 1) On the day before the study, the diabetic subjects received soluble insulin only. In the evening they were connected to a Biostator (Life Science Instruments, Miles Laboratories, Elkhart, Ind., USA) to obtain normoglycaemia by a feedback automated glucose controlled insulin infusion (Insulin Velosulin Human, Nordisk Gentofte A/S, Gentofte, Denmark). The double lumen catheter for continuous blood withdrawal by the Biostator was inserted into a forearm vein of the left arm, another catheter for intermittent blood sampling was placed in a wrist vein on the same side and a third catheter was placed in a right cubital vein for infusions. During the study the subjects kept the left hand and forearm in a heated plexiglas box to ensure arterialization of venous blood. The control subjects were admitted to hospital on the morning of the day of study. At 07.30hours (t=-30) a primed (40btCi), continuous (0.4 btCi/min) infusion of 3-3H-glucose (New England Nuclear, Boston, Mass., USA) was started and continued throughout the study for isotopic determination of glucose turnover. 3-3H-glucose batches contained no radiochemical contaminants as assessed by high pressure liquid chromatography. From 08.00 hours (t = 0) somatostatin (450 btg/h) and insulin (0.15 mU. kg-t-min -1) were infused. At the same time plasma glucose was acutely clamped at 5 mmol/l and maintained at this level for 120 min. At 10.00 hours an infusion of glucagon (Novo Industri A/S, Copenhagen, Denmark) (t.5 ngkg-1. min-1) was commenced. From this stage no upper limit was set for the plasma glucose level, but it was not allowed to fall below 5 mmol/1. Blood for determination of plasma glucose, plasma glucose specific activity, serum insulin, serum C-peptide, plasma glucagon, serum OH, serum non-esterified fatty acid (NEFA) and blood metabolites was drawn every 15 min throughout the study. Plasma glucose was determined every 5 rain by a glucose analyzer. As shown in Figure ] values from -30 to 0 min are designated as pre-values, whereas basal values refer to mean of blood samples taken during the last 30 min of the clamp, just prior to glucagon infusion (90-120 min). Period 1 refers to t 120-180, period 2 to t 180-240 and period 3 to t 240-300 min (i. e. the 1st, 2nd and 3rd hour of glucagon infusion).
Analytical methods
Plasma glucose was determined by a glucose oxidase method, and serum GH and plasma pancreatic glucagon by RIA using wick chromatography [25] . Free insulin was measured by RIA as described previously [26] . Serum C-peptide was assayed employing a commercial kit (Immunonuclear Corp., Stillwater, Minn., USA) and serum NEFA according to Ho and Meng [27] . Blood 3-hydroxybutyrate (BOH), glycerol, lactate, and alanine were assayed by automated enzymatic fluorometric methods [28] . For determination of tritiated glucose activity plasma was deproteinized using 0.3 mol/1 Ba(OH)2 and 0.3 mol/l ZnSO4, after which the supernatant was evaporated under vacuum, resuspended in distilled water, and counted by a liquid scintillation counter after the addition of 5 ml Aqualuma Plus (Lumbac, Schaesburg, The Netherlands). Pre-experimental (pre) values (t:-30--0 min) of plasma glucose were slightly higher in the diabetic group (6.2 + 0.4 vs 5.3 + 0.1 mmol/1, p < 0.05), whereas prevalues of serum insulin, plasma glucagon and serum GH were similar. Pre-levels of serum C-peptide were significantly higher in the control subjects (1.5+0.1 vs < 0.7 pmol/ml) (below lower detection limit);p < 0.05. Basal levels of plasma glucose, serum insulin, and plasma glucagon were similar in diabetic and healthy subjects (Fig.2) .
Calculations and statistical analysis
In both groups plasma glucose increased with time (p < 0.01) the increase was significantly more pronounced in the control group (p < 0.01) (control subjects; from 5.2 + 0.1 to 7.4 + 0.7 mmol/1, diabetic subjects; from 5.2 + 0.1 to 6.4 + 0.7 mmol/1). Serum insulin and GH levels were stable and similar at basal levels during glucagon infusion. Plasma glucagon concentrations increased comparably in both groups (Table 2) .
Basal serum NEFA and blood glycerol levels were similar in the two groups. During glucagon infusion a significant reduction of serum NEFA levels was seen in both groups. Blood glycerol levels were also similar in the two groups and tended to fall in both, but significantly only in the diabetic subjects (Fig. 3) . At all time points BOH-values were higher in the diabetic group (p < 0.01); in both groups the BOH-level gradually fell to approximately half the starting value (55 + 12 to 23 + 6 ~tmol/1 and 10 + 4 to 4 _+ 1 gmol/1, from basal to period 3 in diabetic patients and control subjects respectively); the decrease had already been initiated with the commencement of somatostatin/insulin infusion.
Blood lactate and alanine concentrations were similar in the two groups. Blood lactate levels were stable, whereas blood alan• levels rose very slightly in both groups (Fig. 3) .
Glucose kinetics (Fig. 2, Table 3 ) Basal hepatic glucose production was similar in the two groups (1.2 + 0.3 vs 1.6 + 0.1 mg. kg -1 min-1, NS) . In both groups there was a time-dependent change in HGP (p < 0.05). ANOVA revealed the responses of the control subjects and diabetic patients to be significantly different (p < 0.05). The response in the control group to glucagon infusion was a sharp increase in HGP within minutes, which stayed at a stable high level ( = 3.5 mg. kg-1. rain-1) for approximately 100 min and then gradually decreased, without reaching the basal value within the observed time span. In the diabetic subjects, however, a totally different response was seen. Glucagon increased HGP only moderately and slowly (to 2.2 _+ 0.5 mg.kg -1 .min -1, period 1) and this moderate increase was maintained throughout the infusion period. Following glncagon infusion there tended to be a time-dependent decrease in the glucose infusion rate (M), (0.05 <p < 0.1), this effect was significantly more pronounced in the control group (p < 0.05). Ra increased significantly in both groups with time (p < 0.01), no interaction was recorded. Basal glucose utilisation (Rd) was similar, 2.5 + 0.2 in the diabetic patients vs 2.7 +0.1 mg-kg-l-min -1 in the control subjects, Rd increased with time in both groups (p <0.01) with no significant difference between the increase of the groups.
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Discussion
At the start of the studies (pre-values), plasma glucagon levels were comparably low in the diabetic patients and in the control subjects. This often occurs after overnight blood glucose regulation (Biostator), presumably due to the quite long-term blood glucose normalisation with input of adequate insulin and glucose. Somatostatin suppressed plasma glucagon levels further in both groups to approximately 18 pg/ml, and the increment during glucagon infusion was 25-30 pg/ml ( > 100% increase), or approximately 25% above pre-values. Thus, what was studied here was the effect of an identical increase in plasma glucagon from low normal levels to the concentration usually found in Type i diabetic patients during everyday life.
When glucagon was infused the diabetic patients exhibited: 1(an overall reduced HGP response and 2) an abnormal response pattern with a more sluggish initial increase. These findings point towards a decreased HGP response to glucagon stimulation in the diabetic patients at euglycaemia, as both groups had similar plasma glucagon and insulin levels. No breakthrough of insulin release was evident in the control subjects, as assessed by serum insulin and C-peptide concentrations.
The finding of reduced HGP response is in apparent contrast to the results of Shamoon et al. [30] , who found identical increases in HGP in diabetic and control subjects after glucagon infusion. In their study, however, secretion of insulin was not suppressed by somatostatin. In fact, the higher plasma insulin levels in the control subjects, in their study, with similar HGP rates, also point to a reduced HGP response to glucagon in the diabetic patients.
Diminished hepatic sensitivity to glucagon stimulation has also been found in another clinical condition, namely uraemia [31] . As in diabetes, patients with uraemia are exposed to chronic hyperglucagonaemia and hepatic 'insensitivity' to glucagon might be induced in an equivalent manner to the induction of insulin resistance. Rat hepatocytes from uraemic livers were found to be resistant to glucagon with regard to c~-aminoisobutyric acid uptake and this was found to be due to post-binding events [32] .
It is obvious that the reduced HGP in the Type 1 diabetic subject may further attenuate the already com- Table 3 . Rates of total glucose appearance (Ra), total glucose disappearance (Rd), hepatic glucose production (HGP) and glucose infusion rate (M) (mg. kg-1 min-1) in seven Type 1 (insulin-dependent) diabetic and ten healthy subjects during euglycaemic clamping with infusion of glucagon [12, 33, 34] indicate that the initial response to glucagon is due to glycogenolysis. Subsequently gluconeogenesis is activated, at least with higher glucagon levels, and continues to increase, even when glycogenolysis and HGP are suppressed after a relatively short period. As the impaired diabetic HGP response in our study is most pronounced in the early response phase, this may indicate a reduced and sluggish activation of glycogenolysis at normal blood glucose levels. This cannot, however, be clarified on the basis of the present results.
Basal HGP levels were slightly, though not significantly higher in the control group. A true difference could have been caused by diminished glucagon sensitivity as well as increased hepatic insulin sensitivity in the diabetic group. However, the increase in HGP following glucagon infusion was much higher in the control subjects, which speaks against it being caused by insulin. Other studies have found hepatic insulin sensitivity to be decreased [35, 36] as well as increased [37] and the issue has not been sufficiently clarified. In the basal period, subjects were relatively glucagon deficient, and it cannot be excluded, that the lower response to glucagon in the diabetic subjects, may be overestimated by the lack of a physiological glucagon replacement prior to glucagon stimulation.
Of course, the existing shortcomings of the isotope dilution technique, whether caused by modelling errors or isotope discrimination, necessitates cautious interpretation of tracer-derived data. In the present study maximal glucose turnover rates were below the rate where suppression of HGP is at risk of being significantly overestimated ( < 4 mg. kg -a. rain z), and also the fact that glucose turnover rates tended to be higher in the control group, leading to greater suppression of HGP in this group, implies that our conclusion is reliable.
The fall in lipolysis, evident from the reduced blood glycerol levels prior to glucagon infusion, is presumably secondary to somatostatin/insulin infusion. When glucagon was also infused the decrease continued. This is in agreement with the results of Shulman et al. [38] . These authors found glucagon excess to be associated with inhibition of lipolysis, presumably secondary to glucagoninduced hyperglycaemia rather than a direct hormonal effect [38] . A direct lipolytic effect of glucagon has previously been described, but not in the presence of basal serum insulin levels [39, 40] . The same combined effects of basal serum insulin levels, increasing blood glucose, and reduced supply of NEFA presumably account for the reduction in ketone body-levels found in both groups [40] .
In conclusion, we have found 1) an overall reduced HGP response and 2) an abnormal response pattern to physiologic glucagon stimulation in Type i diabetic subjects. These abnormalities may lead to inappropriate counter regulation following a hypoglycaemic episode.
